Paul, 66, joined the Board of Oxford BioMedica in January 2010. He is a senior pharmaceutical executive with more than 30 years’ experience gained from roles in international pharmaceutical and biotech companies and he has been involved in the development of many drugs and vaccines including Requip, Coreg and Provigil.